CA2211376A1 - Bio-erodible ophthalmic shield - Google Patents

Bio-erodible ophthalmic shield

Info

Publication number
CA2211376A1
CA2211376A1 CA2211376A CA2211376A CA2211376A1 CA 2211376 A1 CA2211376 A1 CA 2211376A1 CA 2211376 A CA2211376 A CA 2211376A CA 2211376 A CA2211376 A CA 2211376A CA 2211376 A1 CA2211376 A1 CA 2211376A1
Authority
CA
Canada
Prior art keywords
bio
traumatized
erodible
gelatin
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2211376A
Other languages
French (fr)
Other versions
CA2211376C (en
Inventor
Alok Nigam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Surgical Inc
Original Assignee
Chiron Vision Corporation
Alok Nigam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Vision Corporation, Alok Nigam filed Critical Chiron Vision Corporation
Publication of CA2211376A1 publication Critical patent/CA2211376A1/en
Application granted granted Critical
Publication of CA2211376C publication Critical patent/CA2211376C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/12—Bandages or dressings; Absorbent pads specially adapted for the head or neck
    • A61F13/122—Bandages or dressings; Absorbent pads specially adapted for the head or neck specially adapted for the face
    • A61F13/124—Bandages or dressings; Absorbent pads specially adapted for the head or neck specially adapted for the face specially adapted for the eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/041—Mixtures of macromolecular compounds

Abstract

Bio-erodible ophthalmic shields comprising gelatin, a glycosaminoglycan (for example chondroitin sulfate) and carboxymethyl cellulose, and a method of treating a traumatized or "dry" eye by administering the gelatin-based ophthalmic shields to the traumatized eye. The ophthalmic shields are bio-compatible and bio-erodible in traumatized, non-traumatized and dry eyes. The gelatin-based ophthalmic shields can further include one or more therapeutically active substances that will be released to the eye.
CA002211376A 1995-02-14 1996-02-13 Bio-erodible ophthalmic shield Expired - Fee Related CA2211376C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/388,159 1995-02-14
US08/388,159 US5518732A (en) 1995-02-14 1995-02-14 Bio-erodible ophthalmic shield
PCT/US1996/001914 WO1996025145A1 (en) 1995-02-14 1996-02-13 Bio-erodible ophthalmic shield

Publications (2)

Publication Number Publication Date
CA2211376A1 true CA2211376A1 (en) 1996-08-22
CA2211376C CA2211376C (en) 2000-10-24

Family

ID=23532942

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002211376A Expired - Fee Related CA2211376C (en) 1995-02-14 1996-02-13 Bio-erodible ophthalmic shield

Country Status (9)

Country Link
US (1) US5518732A (en)
EP (1) EP0809486B8 (en)
JP (1) JPH11500032A (en)
AT (1) ATE207735T1 (en)
AU (1) AU694628B2 (en)
CA (1) CA2211376C (en)
DE (1) DE69616514T2 (en)
ES (1) ES2166436T3 (en)
WO (1) WO1996025145A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387407B1 (en) * 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
WO2000035432A2 (en) * 1998-12-17 2000-06-22 Alcon Laboratories, Inc. Improved viscoelastic compositions and methods of use
US20030138499A1 (en) * 1998-12-17 2003-07-24 Shah Mandar V. Stable surgical irrigating solutions
ES2255987T3 (en) 1999-03-01 2006-07-16 Milcin Therapeutics Llc OPHTHALMIC PREPARATIONS CONTAINING MUCINE.
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
DE10133870A1 (en) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmic agent, use of EGF for the treatment of dry eye syndrome and insert for the administration of EGF to the eye
MXPA04011416A (en) 2002-05-17 2005-09-30 Othera Pharmaceuticals Inc Amelioration of the development of cataracts and other opthalmic diseases.
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
MXPA03011987A (en) 2003-12-19 2005-06-23 Osio Sancho Alberto Method for treating presbyopia by inducing changes in the corneal power and physiology.
DE102004024635A1 (en) * 2004-05-12 2005-12-08 Deutsche Gelatine-Fabriken Stoess Ag Process for the preparation of moldings based on crosslinked gelatin
CN101305052B (en) * 2005-09-09 2012-10-10 渥太华健康研究所 Interpenetrating networks, and related methods and compositions
CA2679066A1 (en) 2007-02-22 2008-08-28 Othera Holding, Inc. Hydroxylamine compounds and methods of their use
US20080243095A1 (en) * 2007-03-26 2008-10-02 Theta Research Consultants, Llc Method and Apparatus for Ophthalmic Medication Delivery and Ocular Wound Recovery
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
US20090142292A1 (en) * 2007-12-03 2009-06-04 Blackwell Richard I Method For The Mitigation of Symptoms of Dry Eye
SI2915529T1 (en) * 2008-05-07 2017-09-29 The Regents Of The University Of California Therapeutic replenishment and enrichment of ocular surface lubrication
US20090297578A1 (en) * 2008-06-03 2009-12-03 Trollsas Mikael O Biosoluble coating comprising anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US20100198348A1 (en) * 2009-01-30 2010-08-05 Hiles Michael C Biomaterials with modified optical character and methods for preparing and using same
EP2585057B1 (en) 2010-06-25 2017-08-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methods of treatment using sterculic acid
CN111290143B (en) 2012-08-10 2023-03-31 奥西奥公司以约利亚健康公司名义经营 Contact lenses and methods of determining the fit of a contact lens for an eye of an individual
JP6989757B2 (en) * 2017-06-19 2022-02-03 澁谷工業株式会社 Manufacturing method and equipment for gelatin cross-linked products
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
JP7311983B2 (en) * 2019-03-01 2023-07-20 大日本印刷株式会社 Gel membrane manufacturing method and gel membrane
WO2022240598A1 (en) * 2021-05-10 2022-11-17 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710796A (en) * 1971-05-14 1973-01-16 C Neefe Corneal drug delivery method
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3914402A (en) * 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
NL188266C (en) * 1975-07-29 1992-05-18 Merck & Co Inc PROCESS FOR THE PREPARATION OF AN ORGANIC IMPLANT.
US4233360A (en) * 1975-10-22 1980-11-11 Collagen Corporation Non-antigenic collagen and articles of manufacture
US4164559A (en) * 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4223984A (en) * 1979-04-04 1980-09-23 Opticol Corporation Collagen soft contact lens
US4264155A (en) * 1979-07-09 1981-04-28 Opticol Corporation Collagen contact lens
US4581030A (en) * 1982-09-30 1986-04-08 Massachusetts General Hospital Collagen replacement prothesis for the cornea
US4505855A (en) * 1982-09-30 1985-03-19 Massachusetts General Hospital Transparent non-fibrilized collagen material by ultracentrifugation
US4600533A (en) * 1984-12-24 1986-07-15 Collagen Corporation Collagen membranes for medical use
SU1321420A1 (en) * 1985-06-19 1987-07-07 Московский научно-исследовательский институт микрохирургии глаза Method of collagen coating for ophthalmological use
US5304169A (en) * 1985-09-27 1994-04-19 Laser Biotech, Inc. Method for collagen shrinkage
US5128134A (en) * 1986-09-17 1992-07-07 Fyodorov Svyatoslav N Ophthalmological collagen coverings
US5263992A (en) * 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
US5156839A (en) * 1987-05-04 1992-10-20 Mdr Group, Inc. Viscoelastic fluid for use in spine and general surgery and other surgery and therapies and method of using same
US5036056A (en) * 1987-07-08 1991-07-30 Martin Kludas Methods for treating damaged corneal, uterine, or cartilage tissue
US5053388A (en) * 1987-11-09 1991-10-01 Chiron Ophthalmics, Inc. Wound healing composition and method
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
FR2627078B1 (en) * 1988-02-16 1994-03-18 Allergan Inc EYE DEVICE
US5137728A (en) * 1988-03-01 1992-08-11 Bausch & Lomb Incorporated Ophthalmic article
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US5304595A (en) * 1988-11-21 1994-04-19 Collagen Corporation Collagen-polymer conjugates
US5264214A (en) * 1988-11-21 1993-11-23 Collagen Corporation Composition for bone repair
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US4946450A (en) * 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5246013A (en) * 1989-12-22 1993-09-21 Massachusetts Institute Of Technology Probe, system and method for detecting cartilage degeneration
US5185152A (en) * 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
US5259998A (en) * 1991-10-04 1993-11-09 Chiron Ophthalmics, Inc. Method for casting dissolvable ophthalmic shields in a mold
US5270051A (en) * 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
JPH08503701A (en) * 1992-10-28 1996-04-23 サイトアーレクス・コーポレーシヨン Ophthalmic solutions and methods of use

Also Published As

Publication number Publication date
AU694628B2 (en) 1998-07-23
WO1996025145A1 (en) 1996-08-22
EP0809486B8 (en) 2002-09-11
US5518732A (en) 1996-05-21
EP0809486A1 (en) 1997-12-03
JPH11500032A (en) 1999-01-06
CA2211376C (en) 2000-10-24
ATE207735T1 (en) 2001-11-15
DE69616514D1 (en) 2001-12-06
ES2166436T3 (en) 2002-04-16
EP0809486B1 (en) 2001-10-31
AU5023196A (en) 1996-09-04
DE69616514T2 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
CA2211376A1 (en) Bio-erodible ophthalmic shield
AU5441690A (en) Glucan/collagen therapeutic eye shields
EE9700286A (en) Controlled release of miotic and mydriatic drugs in the anterior chamber of the eye
AU2611292A (en) Dry eye treatment process and solution
AU649605B2 (en) Retinal, derivatives and their therapeutic use
ZA912797B (en) Dry eye treatment process and solution
EP0142426A3 (en) Ophthalmic formulation containing norfloxacin and related antibiotics
CA2126083A1 (en) Use of app modulators for the manufacture of a medicament for the treatment of amyloidosis
AU9028491A (en) Iontophoretic drug delivery electrode and method of hydrating the same
NZ225578A (en) Regenerated cellulosic fibre of multi-limbed shape, production thereof, and uses
AU4859793A (en) Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
BR9402201A (en) Ophthalmic solution and method to treat the eye against irritation and dryness
AU3693789A (en) New ophthalmic preparation for treating glaucoma
AU3066789A (en) Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases
EP0339502A3 (en) Process for modifying cellulosic membrances for the improvement of their biocompatibility, and apparatus for carrying out the process
DE3479728D1 (en) Derivatives of thiophenesulfonamide, their preparation and pharmaceutical composition for the topical treatment of elevated intraocular pressure
HUT68007A (en) Pharmaceutical compositions for preventing and treating retinal diseases and process for preparing them
AU3909389A (en) Il-1alpha derivatives and medicament for treating thrombocytopenia
CA2150714A1 (en) Syndecan stimulation of cellular differentiation
GB2100599B (en) Pharmaceutical preparation for treating glaucoma and ocular hypertension
IT1098997B (en) PROCEDURE FOR THE APPLICATION OF SUPPORT EYES ON CONSTRUCTION PARTS TO BE SUPPORTED IN A SWINGABLE WAY
AU656349B2 (en) Aramid monofilament with weakly structured skin and process of production thereof
AU6901191A (en) Pharmacologically active substance bpc, the process for its preparation and its use in the therapy
IL135171A0 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
HU910109D0 (en) Process for the production of medical preparations for preventing proline-and lysine-hydroxylase and process for the production of some of the active agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed